NEW YORK (GenomeWeb) – CombiMatrix is developing two new tests that will expand its place in the reproductive health market, one of which will complement existing chromosomal microarray analysis services and the other of which will open CombiMatrix up to a new market segment.

The company is already benefiting from its focus on prenatal and pediatric CMA services, which drove revenues up 13 percent in the first quarter, and the firm has plans to broaden its offerings in the reproductive health arena, CEO Mark McDonough said on an earnings call.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.